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ABSTRACT

OVEREXPRESSION OF HUMAN GLUTAMINE TRANSPORTERS IN RAT
LIVER EPITHELIAL CELLS PROVIDES INSIGHTS INTO THEIR ROLE IN
CELL GROWTH AND POTENTIAL PHARMACOLOGICAL INHIBITION AS
CANCER TARGETS

Aparna Agarwal, M.S.
Department of Biological Sciences
Northern Illinois University, 2017
Barrie P. Bode, Director

The amino acid Glutamine not only serves several important metabolic and
physiological roles in the body, but is also a coveted substrate that drives the growth of
tumors. Unlike normal liver cells (hepatocytes) that transport glutamine through “System N”
(SNAT3, SNAT 5), human hepatoma cells (liver cancer cells) take up glutamine several
times faster through transporters distinct from System N, such as System ASC (e.g. ASCT2)
and System B0, + (e.g. ATB0, +). Previous studies have implicated these transporters in
driving a wide variety of human cancers and have also shown that silencing these
transporters, especially ASCT2, lead to apoptosis and inhibited cell proliferation. This study
was aimed at over-expressing ASCT2 and ATB0, + transporters in Rat Liver Epithelial cells
(RLE) to screen potential pharmacological inhibitors and study the effect of over-expression
on cell growth and proliferation. Results show that over-expression of these transporters did
not manifest into higher growth rates and failed to provide the cells with any advantage in
glutamine deprived conditions. While small molecular inhibitors like glutaminyl-

paranitroanilide (GPNA) displayed selective inhibitory effects toward glutamine transport
and ASCT2, they were not specific, and exerted only marginal effects on amino acid
accumulation in the presence of normal compliments of amino acid substrates. Alpha(methylamino) isobutyric acid (MeAIB) displayed no substantial effect on the transport
activity indicating negligible role of System A transporters in glutamine import.
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CHAPTER 1
BACKGROUND

Overall Goals

Over the last decade, derangements in cancer metabolism have been intensely
studied and identified as potential targets for therapy. Among these derangements are an
increased reliance on the glycolytic metabolism of glucose (the “Warburg Effect”) and
enhanced consumption of the amino acid glutamine. Past research on the quest to find the
metabolic “Achilles’ heel” of cancer, including work from our laboratory, has demonstrated
that glutamine transporters may be promising targets for cancer therapy. Initially, glutamine
transporters were identified as potential targets based largely on enhanced expression in
malignant tumors, but the physiological effect of transporter over-expression on cancer cell
growth has not been determined. Two sodium-dependent glutamine transporters, ASCT2
(encoded by the SLC1A5 gene) and ATB0, + (encoded by the SLC6A14 gene) have been
particularly implicated in driving the growth of a wide variety of human cancers. Each
transporter was overexpressed in rat liver epithelial (RLE) cells to determine the effects of
transporter overexpression on cellular growth, proliferation under nutrient-limiting
conditions, short-term and long-term glutamine and arginine transport and accumulation,
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and the relative susceptibility of both to a small molecular inhibitor of amino acid transport,
glutaminyl-paranitroanilide (GPNA).

Importance of Glutamine in Normal Physiology and Cancer

Glutamine or 2-amino-4-carbamoylbutanoic acid is a neutral (polar, at physiologic
levels) amino acid that plays a critical role in regulating metabolism in humans. The
concentration of Glutamine circulating in blood is the highest ranging from 600µM 1000µM and it is now being considered as “conditionally-essential”. Human hepatoma cells
take up glutamine at a significantly higher concentration than normal human hepatocytes.
Paradoxically, the uptake of glutamine is encouraged in critically ill patients but is targeted
in anti-cancer therapies (Bode, 2016).
Glutamine serves as the major source of carbon and nitrogen for various metabolic
pathways such as de novo biosynthesis of purine and pyrimidines, hexosamine biosynthesis,
glutathione biosynthesis, lipid biosynthesis etc. Cells can easily grow and proliferate even in
a glucose free media containing sufficient amount of glutamine. (Abcouwer, Bode, Souba,
1996).
Glutamine also participates in tri carboxylic acid (TCA) cycle by entering as αketoglutarte and serving as a major respiratory fuel. Glutamine is first deaminated to
glutamate by glutaminase and then converted to α-ketoglutarte by glutamate dehydrogenase
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or amidotransferase (Krebs, & Bellamy, 1960). Since glycolysis provides compounds that
are crucial for cell growth and proliferation, cancer cells were discovered to carry out
glycolytic metabolism even at sufficient oxygen levels through oncogenic pathways such as
Myc and E2F/Rb, that are responsible for the increased glutaminase and glutamine
transporter expression. This is known as the “Warburg effect” named after Otto Watburg,
the scientist who discovered it. Epithelial carcinoma cells have also been found to induce a
glycolytic and autophagic phenotype in stromal cells, also known as Cancer associated
fibroblasts (CAFs) which in turn provides cancer cells with lactate and autophagy-generated
glutamine and fatty acids, a relationship designated as “Metabolic asymmetry” or “Reverse
Warburg Effect” (Ko, et al., 2011; Martinez-Outshoorn et al., 2014). Glutamine also
regulates redox balance, mTOR signaling, apoptosis and autophagy (Hassanein, et al.,
2013).

Glutamine Metabolic Cycles
Intercellular glutamine cycles in brain and liver have been studied profusely.
Glutamine enters the liver tissue by portal or hepatic arterial circulation and is transported to
most of the hepatocytes lining the hepatic acinus and utilized in a myriad of metabolic
pathways. To maintain the net glutamine balance across the liver, a small portion of
hepatocytes (3-5%) around the central venous outflow, re-synthezise glutamine by
glutamine synthetase (GLUL) for export into the venous circulation. Liver is thus
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responsible for scavenging ammonia that has escaped detoxification and utilizing it
alongwith glutamate to regenerate glutamine. Tumors disrupt these intercellular glutamine
cycles and develop their own to operate between the tumor and the surrounding stromal cells
(Bode, 2015)

Figure 1: Structure of Glutamine
(www.sigmaaldrich.com).com)

Glutamine Transporter Families

Incidence of Human Hepatocellular carcinoma (HCC) is increasing worldwide
including United States primarily due to chronic hepatitis C virus infection (de Oliveria
Andrade et al., 2009). An array of glutamine transporters belonging to Solute Carrier
families (SLCs) are responsible for transporting glutamine and various other amino acids
across cell membrane in HCC. These transporters are integral membrane proteins encoded
by specific genes with distinct physiological and functional properties. They have been
discriminated based on their substrate specificity, ion dependence and kinetic and regulatory
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properties. The names of the genes for each transporter begin with “SLC” (solute-linked
carrier), followed by the number of the gene family, an “A” for amino acid transporter and
finally the number assigned to the transporter in the gene family. The genes are italicized.
For e.g., the gene encoding the transporter ASCT2 is written as SLC1A5 where SLC stands
for solute carrier, 1 is the number allotted to the gene family, “A” denotes amino acid
transporter and 5 is the number given to the transporter in this gene family. This
nomenclature is maintained and constantly updated in SLC table database that are available
at the link: http://slc.bioparadigms.org/ (Bode, 2017).
The amino acid transporters that have been implicated in driving growth in hepatoma
cells in HCC are ASCT2 (SLC1A5), LAT1(SLC7A11) , ATB0,+ (SLC6A14) and most
recently xCT (SLC7A11). xCT exchanges cystein for intracellular glutamate to sustain
glutathione biosynthesis (Bode, 2015).
ASCT2
ASCT2 (SLC1 family) is a broad specificity Na+-dependent neutral amino acid
exchanger with glutamine as its primary substrate. It is named as such because it is
responsible for transporting amino acids like alanine, serine and cystein. It also exhibits
“System ASC” like properties and is insensitive to inhibition by an amino acid analogue
alpha-(methylamino)-isobutyric acid (MeAIB) (Killberg, et al., 1979). It can mediate the bidirectional transport of glutamine. The other SLC1 family member ASCT1 transports small
neutral amino acids like ASCT2 but does not transport glutamine and asparagine (Scalise, et
al., 2014). There is a 10-fold increase in glutamine uptake via ASCT2 in HCC. (Bode et al.,
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2002). This differential expression of ASCT2 in normal and cancerous cells makes it a
promising therapeutic target.
The first human isoform of ASCT2 was isolated in 1996 from human placenta. Most
recently the human ortholog has been modeled. Human and rat ortholog proteins share 79%
sequence identity. The homology model of human ortholog has two glycosylation sites
which are exposed extracellularly corroborating with the proposed orientation of this
transporter in the membrane (Pochini et al., 2014).
Cell growth and cell cycle progression was found to be inhibited in human breast
cancer cells when ASCT2 mediated glutamine transport was inhibited by certain
pharmacological inhibitors. GPNA (L-γ-glutamyl-p-nitroanilide) significantly decreased
ASCT2 function in breast cancer cells (Geldermalsen et al., 2015), prostate cancer, lung
cancer (Wang, et al., 2015), etc. is considered specific to ASCT2. But previous studies in
our lab place the specificity of ASCT2 in question as GPNA affected the activity of other
transporter families. Also, it has been shown that silencing ASCT2 in hepatoma cells causes
reduction in mTOR activity leading to apoptosis (Fuchs, et al., 2007).
LAT 1
ASCT2 works in conjunction with another neutral amino acid transporter LAT1
(Fuchs, Bode, 2005) encoded by the gene SLC7A5. It is a Na+-independent bidirectional
transporter that regulates the efflux of L-glutamine while bringing in L-leucine
simultaneously. ASCT2 and LAT1 work together to serve many functions in a cell including
enhancement of growth signaling through activation of mammalian-target-of-rapamycin
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(mTOR) (see figure 3). mTOR is a serine threonine kinase which is responsible for the
activation of cap-dependent protein translation and inhibits autophagy (Fuchs, Finger, Onan
& Bode, 2007; Nicklin et al., 2009). Apart from LAT1, two other members of this family
mediate glutamine uptake: y+LAT1 (SLC7A7) and y+LAT2 (SLC7A6). These SLC7 family
members function as heterodimers with the SLC3 family non-transporter chaperone protein,
4F2 heavy chain, or 4F2hc (Fotiadis, Kanai and Palacin, 2013).
ATB0, +
Another transporter belonging to System B0, +; ATB0, + (encoded by SLC6A14) is a
Na+- and Cl--dependent transporter that accepts neutral and cationic amino acids. It is a
concentrative transporter that mediates net glutamine uptake (Bode, 2017). Glutamate and
aspartate are the only two amino acids that are not recognized as substrates by ATB0,+. It is
expressed at low levels in normal tissues but is found to be up-regulated in various cancers
like colon cancer, cervical cancer and estrogen receptor-positive breast cancer
(Karunakaran, 2011). Apart from being targeted for anti-cancer therapies, ATB0,+ has
demonstrated the ability to transport NOS (Nitric oxide synthase) inhibitors and anti-viral
agents like acyclovir and ganciclovir into the cells (Ganapathy et al., 2010).
SNATs
Sodium coupled neutral amino acid transporters (SNATs) belong to SLC38 gene
family and are distinguished as System N and System A based upon their functions and
regulation. Both systems are Na+-dependent and have two major differences: System A
transporters mediate only inward transport of their substrates and accept MeAIB (an amino
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acid analogue) as their substrate while System N does not. System N governs the bidirectional transport of glutamine via a sodium-proton exchange mechanism. SLC38 family
has 11 members but only seven have been characterized to-date: System A: SNAT 1
(SLC38A1), SNAT 2 (SLC38A2), SNAT4 (SLC38A4) and SNAT 8 (SLC38A8), System N:
SNAT 3 (SLC38A3), SNAT 5 (SLC38A5) and SNAT 7 (SLC38A7) (Mackenzie, et al.,
2004).
In normal rat and human hepatocytes, glutamine transport was found to be primarily
mediated by System N transporters, whereas ASCT2 was shown to mediate significantly
enhanced glutamine transport rates in human liver cancer cells. The transporter- shift can be
attributed to the fact that in a poorly vascularized tumor microenvironment with a low
glutamine concentration, a lower Km may prove more effective. Faster growing hepatomas
were found to have low glutamine levels, so ASCT2 mediates the exchange of relatively
abundant intracellular amino acids for the more coveted extracellular ones like glutamine
(Bode, et al., 2002; Bode, et al., 1995). Previous studies have shown that ASCT2/ATB0+ are
essential for cell growth and viability in cancer and knockdown of these transporters,
primarily ASCT2, reduced cell proliferation and induced cell death (Fuchs, et al., 2003;
Geldermalsen, et al., 2015).
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Figure 2: Tertiary Active Transport of Amino Acids: SNATs (Sodium coupled neutral
amino acid transporters, encoded by gene SLC38) are responsible for mediating the net
uptake of glutamine in hepatocytes However, in cancer where the demand for glutamine
increases, the tramsport of glutamine shifts to high affinity glutamine transporters like
ASCT2 (SLC1A5) and ATB0, + (SLC6A14) (Bode, Kaminski, Souba, Li, 1995). Intracellular
glutamine is exchanged in a sodium independent manner for leucine for activation of
mTOR growth signaling by LAT1 (SLC7A1) (Fuchs, Bode, 2005). ATB0,+ is also
responsible for maintaining intracellular pools of Arginine, another amino acid whose
uptake has been shown to be upregulated in cancer (Gupta, Miyauchi, 2005). Arginine is
transported out of the cells by y+LAT1/2 (SLC7A7/6) in a Na+ independent manner in
exchange for neutral amino acids like lecine (Na+ dependent uptake) for the activation of
mTOR growth signaling (Pochini et al., 2014).
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Table 1: SLC Table for amino acid transporters implicated in driving cancer growth

Table 1: SLC Table for amino acid transporters implicated in driving cancer growth
Gene name

SLC1A5

Protein
name
ASCT2,
AAAT

System ASC

Transport
type
C/ Na+/ E/
amino acids

ATB0,+ , βalanine
carrier
system

SLC6A14

SLC7A5

Aliases

LAT1

[4F2hc],
4F2lc,
system L

E (similar
intra- and
extracellular
selectivities,
lower
intracellular
apparent
affinity)

Substrates

Tissue and
cellular
expression
L-Ala, L-Ser, lung, skeletal
L-Cys, Lmuscle, large
Thr, L-Gln,
intestine,
L-Asn
kidney,
testis,
adipose
tissue
neutral,
lung, trachea,
cationic
salivary
amino acids
gland,
mammary
gland,
stomach,
pituitary
gland,
intestine,
uterus,
prostate,
testis
large neutral brain, ovary,
L-amino
testis,
acids, T3,
placenta,
T4, Lspleen,
DOPA, BCH colon, bloodbrain barrier,
fetal liver,
activated
lymphocytes,
tumor cells

(Kanai Y. et al., 2013; Pramod A.B., et al., 2013; Fotiadis D., et al., 2013;
http://slc.bioparadigms.org/). Transport type: E = Exchanger; C = Co-transporter
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Table 2: System A and System N Sodium coupled neutral amino acid transporter
family
Gene name

Protein
name

Aliases

Transport
Type

Substrates

SLC38A1

SNAT1

ATA1,
NAT2, SAT1

C / Na+

SLC38A2

SNAT2

ATA2, SAT2

C / Na+

SLC38A3

SNAT3

SN1

C / Na+, E /
H+

L-Gln, LAla, L-Asp,
L-Cys, LHis, L-Ser
L-Ala, LAsp, L-Cys,
L-Gln, LGlu, L-His,
L-Met, LPro, L-Ser
L-Gln, LHis, L-Ala,
L-Asp

SLC38A4

SNAT4

ATA3,
NAT3,
PAAT

C / Na+

SLC38A5

SNAT5

SN2

C / Na+, E /
H+

L-Ala, LAsp, L-Cys,
L-Glu, LSer, L-Thr
L-Gln, LAsp, L-His,
L-Ser

Tissue and
cellular
expression
brain, retina,
heart,
placenta,
adrenal gland
ubiquitous

liver, skeletal
muscle,
kidney,
pancreas
brain, retina,
liver, kidney,
adipose
tissue
stomach,
brain, liver,
lung, small
intestine,
spleen,
colon, kidney

SNATs are responsible for amino acid transport in normal hepatocytes (Schioth H.B., et
al., 2013; http://slc.bioparadigms.org/). Transport type: E = Exchanger; C = Cotransporter).
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Amino Acid Transport Inhibitors
In various studies, GPNA or L-ϒ- glutamyl-p-nitroanilide (a glutamine analogue)
has been considered a specific ASCT2 inhibitor (Esslinger et al., 2005; Schulte, Dawson,
2015; Takahashi, Uchida, 2015) but previous experiments conducted in our lab indicated
that GPNA might be affecting other transporters systems too. Therefore, GPNA and other
small molecular inhibitors like BCH (2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid) ,
MeAIB (System A-specific substrate, alpha-(methylamino) isobutyric acid), Betaine (Trimethyl glycine, subtype-selective inhibitor of SNAT 2 and SNAT 4) (Nishimura, Yagi et al.,
2014) and β-alanine (a substrate for ATB0, + ) were used determine their effect and
specificity on short-term and long term glutamine and arginine transport.
Both ASCT2 and ATB0, + were stably expressed in Rat Liver Epithelial (RLE) cell
lines in order to exclude interferences by the activity of other human amino acid transporters
in the cells. The studies presented here were designed to determine the utility of System
ASC (ASCT2) and System B0, + (ATB0, +) in driving cellular growth and their physiological
significance in amino acid uptake and accumulation.
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Figure 3: Inhibition of the Tertiary Active Transport: GPNA or L-ϒ- glutamyl-pnitroanilide inhibits glutamine uptake by ASCT2 at millimolar levels (Schulte et al., 2015).
MeAIB or alpha-(methylamino) isobutyric acid is a non-metabolizable amino acid analogue
used to distinguish System A and System N transporters. System A transporters accept
MeAIB as a substrate while System N does not (Bode, 2015). Betaine or tri methyl glycine is
a subtype-selective amino acid for SNAT 2 (Nishimura, et al., 2014). ATB0,+ has been shown
to transport β-alanine with low affinity (Anderson, Ganapathy, Thwaites, 2008).

CHAPTER 2
MATERIALS AND METHODS

Cell Culture
The RLE-13 (Rat Liver Epithelial) cell line was used for this project, and originally
obtained from Dr. Snorri Thorgeirsson at the National Cancer Institute in the mid-1990’s
(Garfield, Huber, Nagy, Cordingley, Thorgeirsson, 1988). The cell line and the transfectants
were incubated and maintained at 370 C in a humidified atmosphere of 5% CO2 – 95% air in
Dulbecco’s modified eagle medium (DMEM, 4.5mg/ml D-glucose) (Gibco; Grand Island,
NY) supplemented with 10% triple 0.1μm filtered fetal bovine serum (FBS)(Atlanta
Biologicals; Lawrenceville, GA), 2mM L- glutamine (Thermo Scientific; Waltham, MA).
The cells were kept in 25 cm2 Falcon T-flasks with 0.2 μm vented blue plug seal caps
(Becton, Dickison and Co; Franklin Lakes, NJ), 100mm plates, 6-well plates, 12- well plates
and 24-well plates (all from Corning; Corning, NY). All cell count measurements in this
study were performed using a counting chamber obtained from Hausser Scientific Co.
(Horsham, PA) and Nikon Phase Contrast Microscope obtained from Frank E. Fryer Co.
(Carpentersville, IL).
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DNA Transfection
The plasmid constructs for target genes SLC1A5 (ASCT2), and SLC6A14 (ATB0,+)
were obtained as E.coli stocks (60% glycerol and stored at -800 C), in the pTCP expression
vector (TransOMIC Technologies inc. Huntsville, AL) driven by a CMV promoter sequence
and a puromycin selectable marker.
A working concentration of each plasmid was created by growing up 50 ml cultures
of E.coli in low salt LB-Lennox broth (Fisher Scientific; Fair lawn, NJ) with 8% glycerol
(Fisher Scientific; Fair Lawn, NJ) and 100μg/ml ampicillin (Fisher Scientific; Fair Lawn;
NJ). The cultures were incubated at 370 C for 16 hrs. A PureYield TM Promega Plasmid
Midiprep was used to extract and purify plasmid stocks according to the manufacturer’s
protocol (Promega; Madison; WI). The final elution volume for each stock was 600μl of
nuclease-free water. A nanodrop 2000 Micro-Volume UV-Vis Spectrophotometer (Thermo
Scientific; Waltham, MA) was used to quantify the stocks and were kept at -200 C.
RLE cells were plated in 100 mm plates at a concentration of 2.16 x 106 cells/ml and
the cells were 80% confluent on the day of transfection. A NeonTM Transfection System
(Invitrogen, Carlsbad, CA) was used for transfecting cells by electroporation. Cells were
trypsinized and re-suspended in Resuspension Buffer R at a final density of 1.0 x 107
cells/ml. The plasmid DNA at a concentration of 3 µg was gently mixed with 120 µl of cell
suspension in a microfuge tube. This mixture was aspirated into the NeonTM tip with the help
of a NeonTM Pipette. A NeonTM tube (placed on the NeonTM Pipette Station) was set up with
3 ml of Buffer E2 and NeonTM pipette was fixed in the tube. Desired pulse conditions (1350
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Volts for 30 milliseconds) were set on the device and an electric pulse was delivered to the
cells.
The electroporated cells were transferred into 11 ml antibiotic-free DMEM in
100mm plates. At 72-hour post transfection antibiotic free media was aspirated and replaced
with selective media [ 4 µg/ml Puromycin (Gibco®; Grand Island; NY)]. This concentration
of Puromycin was determined by establishing a kill curve. To determine kill curve, RLE
were plated at 5x104 cells per well in a 12-well plate and incubated overnight at 370 C. When
the cells reached 70-80% confluence, normal growth medium was aspirated and replaced
with puromycin containing medium at concentrations of 0.5, 1.0, 1.0, 2.0, 3.0, 4.0, and 5.0
μg/ml. The plate was observed daily to determine the concentration that kills 100% RLE
within three days of antibiotic addition.
The viable colonies were isolated using sterile polystyrene cloning cylinders (RPI
Research Products International; Mt. Prospect; IL) and detachment with TrypLEzyme
(Gibco®; Grand Island; NY). Each colony was grown in a separate 25 cm2 Falcon T-flask.
Once confluent, the colonies were screened for cognate transporter expression by western
blotting, glutamine transport assays and RT-qPCR. The samples were subjected to 40 cycles
of amplification.
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Western Blot Analysis
Protein concentrations for all protein samples used in this study were measured with
a nanodrop 2000 Micro-Volume UV-Vis Spectrophotometer, and 20 μg of protein from each
sample was prepared in 2% SDS, 10% glycerol, 62.5mM Tris-HCl (pH 6.8), 0.05%
bromophenol blue (Fisher Scientific, Fair Lawn, NJ), and 50mM dithiothreitol (DTT)
(Fisher Scientific, Fair Lawn, NJ). Protein samples were allowed to separate by
electrophoresis on a 4-20% Mini-Protein® TGX precast polyacrylamide gels (Bio-Rad;
Hercules; CA) for 45 minutes at 150 volts.
Separated proteins were transferred from gels to membranes by using Invitrogen TM
NovexTM Semi Dry Horizontal Blotter (Thermo Fisher Scientific; Waltham; MA) for 10 min
at 20 volts.
An Immobilon® Transfer membrane (Merck KGaA; Darmstadt; Germany) was used
for ASCT2, E-cadherin and YAP western blots. The membranes were incubated overnight at
40 C with primary antibody in blocking buffer [5% Bovine serum albumin (BSA) and 0.1%
Tween-20 in Tris-Buffered saline (TBS) solution (all from Fisher Scientific; Fair Lawn, NJ)
(1:2000). Primary polyclonal rabbit IgG antibody against ASCT2 was obtained from
Fitzgerald Industries (Acton, MA) and was used at a concentration of 1:400. After the
primary incubation, membrane was washed three times in wash solution [ 0.1% Tween-20 in
TBS solution] and then incubated for one hour at room temperature with secondary antibody
in blocking buffer. Secondary HRP-conjugated anti-rabbit IgG antibodies were obtained
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from Cell Signaling (Danvers; MA) and used at a concentration of 1:1000. The
immunoreactive bands were visualized by adding 10 ml of chemiluminescent substrate [1X
LumiGLO® and 1X Peroxide (both from Cell Signaling; Danvers; MA)], incubating for 1
min at room temperature and imaging with G:Box Chemiluminescence Imager (Syngene;
Frederick; MD) and GeneSnap image acquisition software (Syngene; Frederick; MD). The
molecular size of the chemiluminescent bands was determined by comparison to a
biotinylated ladder (Cell Signaling; Danvers; MA). The HRP-linked anti-biotin antibody for
biotinylated ladder was obtained from Cell Signaling (Danvers; MA) and used at a
concentration of 1:2000.

Amino Acid Transport Assays
Measurement of initial-rate Na+ dependent L-glutamine and L-leucine and Larginine uptake was performed by radiotracer analysis using the cluster tray method
previously described in detail (Bode, et al., 2002). RLE cells and transfectants were plated
in 24-well plates at a density of 1.0X 105 cells per well. Initial rate measurements were taken
using two radiolabeled amino acids: L-[G-3H] glutamine and L-[G- 3H] arginine (PerkinElmer; Shelton, CT). These radiotracers were diluted to 4 μCi/ml in the presence of
unlabeled glutamine and arginine at 50μM. Cells were exposed to uptake mix for 30 sec at
37°C, immediately followed by three washes with ice-cold phosphate-buffered saline
solution. Intracellular radiolabeled glutamine/arginine was extracted using a lysis buffer
[0.2% SDS and 2 N NaOH], and the lysates were incubated at room temperature for 30
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minutes after which 100 μl of each lysate was neutralized with 10 μl of 2 N HCl and counted
using a Perkin-Elmer Tricarb 2810 TR liquid scintillation analyzer (PerkinElmer®; Shelton;
CT). To determine the protein concentration, 10 μl of the remaining lysate was measured
with the bicinchoninic acid (BCA) method (Pierce Chemical; Rockford; IL). Uptake
measurements were expressed as nmol AA·mg-1 protein·time (s / min)-1, and all
measurements were normalized to cellular protein content. Initial rate transport velocities
are expressed as the average ± SD of at least four separate determinations. The transport
data were analyzed for significant differences using a t-test, with P < 0.050 considered to be
significant.
To determine the contribution of each transporter in amino acid metabolism under
physiological conditions, short-term and long-term uptake assays were performed in DMEM
supplied with FBS and 1 mM glutamine. The uptake was measured at five time-points; 1
min; 10 min; 30 min; 60 min and 120 min. Transport inhibition studies were also conducted
under above mentioned physiological conditions in the absence and presence of small
molecular transporter inhibitors; GPNA (1 mM) (MP Biomedicals; Solon; OH); BCH (5
mM) and MeAIB (10 mM) (Sigma Chemical; St Louis; MO); β-alanine (10mM) and
Betaine hydrochloride (10 mM) (Acros Organics; NJ). Intracellular radiolabeled
glutamine/arginine/leucine was extracted and counted by utilizing the methods for 30 sec
initial-rate amino acid uptake assays and protein concentration was determined using the
BCA method. Uptake measurements were expressed as nmol AA·mg-1 protein·time-1 (in
min), and all measurements were normalized to cellular protein content. Short-term and
long-term transport velocities are expressed as the average ± SD of at least four separate
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determinations. The transport data were analyzed for significant differences using a t-test,
with P < 0.050 considered to be significant.

mRNA Expression Assay (RT-qPCR)
Cell lines were plated at 1 x 105 cells per 150 mm plate. When the cells reached 8090% confluence, an RNA preparation was performed by harvesting the cells in TRIzol®
reagent (Life Technologies, Grand Island, NY), followed by centrifugation at 30,000 x g.
The upper aqueous phase containing the RNA was harvested, to which 1/10 volume of 4 M
sodium acetate added. RNA was precipitated by the addition of 600 μl of 100% EtOH (20°C), vortexing, and centrifugation at 30,000 x g. The RNA pellet was subsequently
washed with 1 ml of 70% EtOH to remove salt, centrifuged, and allowed to air-dry prior to
the addition of (20 – 50 μl RNase-free water, depending on pellet size), triturated, and
measured for RNA content via the Nanodrop 2000 Micro-Volume UV-Vis
spectrophotometer. Samples were stored at -800 C until use.
One μg of total RNA was used from each sample for the subsequent reverse
transcription reactions. Reverse transcriptase quantitative polymerase chain reaction (RTqPCR) was performed using proprietary TaqMan® Gene Expression Assay primers exclusive to
human ASCT2 and human ATB0, + and all measurements were normalized to two housekeeping
genes (HKG, also known as reference genes): Calnexin (CANX) and Glyceraldehyde -3
phosphate dehydrogenase (GAPDH) (Applied Biosystems; Foster City; CA).
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cDNA was prepared using the Promega ImProm-II Reverse Transcription System
(Madison, WI). Total RNA (1μg/reaction) was combined with 0.5μl/reaction oligo dT
primer (Promega; Madison, WI), and nuclease-free water to a final volume of 5 μl/reaction
in nuclease-free, thin-walled 0.5ml reaction tubes (USA Scientific, Ocala, FL). The RNA
solution was heated at 70⁰C for 5 minutes, then cooled for 5 minutes on ice. Reverse
transcription master mix was assembled using ImProm-II™ 5X Reaction Buffer 4.0 μl/
reaction, 25 mM MgCl2 (final concentration 1.5–8.0 mM) 1.2–6.4μl/reaction, dNTP Mix
(0.5 mM each dNTP) 1.0 μl/ reaction, rRNasin (Recombinant RNasin® Ribonuclease
Inhibitor) 0.5 μl (20 u)/reaction, nuclease-free water for a final volume of 15.0 μl/reaction,
and 1X ImProm-II™ Reverse Transcriptase per 20 ul final volume of 5 μl RNA mix and 15
μl master mix/reaction. Nuclease-free water was substituted for the reverse transcriptase in –
RT reactions. All Quantitative reverse transcription polymerase chain reactions (RT-qPCR)
were carried out using an Eppendorf Mastercycler® ep realplex (Eppendorf, Hauppauge,
NY). Each run was performed a minimum of three times, and within each run, each sample
was run in triplicate for each target gene. These experiments strictly complied with MIQE
(Minimum Information about Quantitative Real-Time PCR Experiments) guidelines.
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Cell Growth (XTT) Assay
Growth studies were conducted using the XTT protocol. XTT (2,3-Bis(2-methoxy-4nitro-5- sulfophenyl)-2H-tetrazolium-5- carbox-anilide) is a yellow tetrazolium salt that is
cleaved to a formazan, a soluble orange dye, by the succinate-tetrazolium reductase system
in the mitochondria of metabolically active cells, measured by light absorption at 490nm in a
microplate reader. Cells were seeded in 96 well plates at a density of 5 x 103 cells/well in
phenol free DMEM (Corning; Manassas, VA) supplemented with 10% triple 0.1 μm filtered
fetal bovine serum (FBS) (Atlanta Biologicals; Lawrenceville, GA), 2 mM L- glutamine
(Thermo Scientific; Waltham, MA) and 4.5 g/L D-glucose (Fisher Scientific, fair Lawn, NJ).
The cells were incubated at 37° C for 24, 48, 72 and 96 hours. After their respective
incubation times, they were treated with 50 µl/well of the XTT working solution [1.25 ml
XTT Reagent and 25 µl XTT Activator (both from Trevigen; Gaithersburg; MD)]. Cells
were incubated for one hour after the treatment and absorbance was measured at 490 nm and
630 nm with an Epoch Microplate Spectrophotometer (Biotek Intruments; Winnoski; VT)
and a Gen 5TM software (Biotek Instruments; Winooski; VT). Averages of the 6 replicates
for each cell line were determined and data was plotted as cell number per well versus
absorbance.
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CHAPTER 3

RESULTS

Transfection of RLE

RLE (Rat Liver Epithelial) cells were transfected using a pTCP vector with a CMV
promoter sequence and a puromycin selectable marker (Figure 4).

Figure 4: Illustration of the pTCp : MGC (Mammalian gene
collection) Expression-ready vector from TransOMIC Technologies
(Retrived from: http://www.transomic.com/Vectors-and-

Maps/pTCP.aspx).
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Stable RLE transfectants were generated through electroporation. Electroporation
was chosen as the preferred method for transfection because of its applicability in the
production of stable transfectants of all cell types. Once optimum electroporation conditions
are determined, a large number of cells can be transfected in a short time (please refer to
MATERIALS AND METHODS for the specific electroporation conditions used for RLE).
Electroporation can result in a lot of cell death due to high voltage pulses and inadequate
cell membrane repair. Substantial amount of cell death was observed amongst the freshly
transfected cell population after the normal media was replaced with the selective one.
Eventually, viable transfectants developed small colonies in the petri dish. 7-8 colonies
from each transfected population of cells were isolated using cloning cylinders and allowed
to grow in separate T25 flasks.
After the flasks were 70-80% confluent protein was extracted from each individual
colony followed by western blot analysis to probe for ASCT2 protein expression. There was
a considerable overexpression of ASCT2 protein in colonies 4 and 6 but was nearly
undetectable in rest of the colonies (Figure 5). To support the western blot evaluations for
ASCT2 protein expression, initial rate transport analysis was performed using 3Hradiolabeled L-glutamine to determine the impact of overexpression on the functional
activity in two colonies (#4 and #6) as compared to the empty-vector control.
There was higher Na+-dependent initial rate glutamine uptake in colony # 6 as compared to
colony # 4 (Figure 6). The enhanced ASCT2 expression in the colonies closely
corresponded to the high protein expression in western blot analysis. Colony # 6 was thus
selected for further experiments on ASCT2.
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ASCT2 ͌ 50kDa

GAPDH ͌ 35kDa

Figure 5: ASCT2 Protein Expression Across Seven RLE
Colonies: Protein expression was measured by western blot. The
chemiluminescent bands for ASCT2 in each colony and in RLE
empty-vector (EV) control are shown in comparison to GPADH
protein detected on the same blot to control for loading error.

Avg. Gln Transport nml*mg protein*
30s-1

Glutamine Transport in RLE ASCT2
0.35

*

0.3
0.25
0.2

*

0.15
0.1
0.05
0
RLE EV

ASCT2-6

ASCT2-4

Figure 6: Na+-dependent Glutamine (L-[3H] Gln) Initial-rate Uptake
in ASCT2 Overexpressing RLE: Transport of 10 μM L-glutamine was
measured. Due to Na+ -dependence of ASCT2-mediated glutamine
uptake, the transport values obtained in the absence of extracellular Na+
(diffusion and Na+ -independent uptake) were subtracted from those in the
presence of Na+ to yield Na+ -dependent rates.

26

Unfortunately, unlike ASCT2, no reliable antibodies are available to probe for
ATB0,+, so RT-qPCR and arginine transport activities were collectively used to screen for
forced overexpression of this transporter. Since ATB0, + utilizes both Na+ and Cltransmembrane gradients to transport glutamine (Pochini et al., 2014), in order to measure
the Cl- independent initial-rate glutamine uptake by the RLE ATB0,+ transfectants,
functional analysis was performed. Apart from the regular sodium-free Krebs-Ringer
phosphate buffer (Choline KRP) and sodium-containing Krebs-Ringer phosphate buffer
(NaKRP), chloride-free NaKRP was prepared using sodium or potassium gluconate salts in
the buffer composition. It was hypothesized that lack of chloride gradient would render
ATB0,+ incapable of transporting glutamine. The results indicated that along with the RLE
ATB0,+ cells, glutamine uptake was significantly reduced in the empty vector control cells as
well in the absence of extracellular chloride, indicating that the role of chloride gradient in
comprehensive amino acid transport is significant, and not a useful indicator of ATB0,+
activity due to low signal-to-noise considerations (Figure 7).
As chloride-dependence was not a useful indicator to assess ATB0, + activity,
arginine transport was used as an alternative, as this transporter transports both arginine and
glutamine, with a preference for the former (Sloan and Mager, 1999). The results indicated
that arginine transport was indeed higher in ATB0, + transfected RLE cells relative to empty
vector control cells (Figure 8).
Following the initial-rate glutamine and arginine uptake assays, RLE ASCT2 and
RLE ATB0, + cells were also screened by RT-qPCR analysis to validate enhanced transporter
expression. The results of those analyses are shown in Tables 3 – 5.

27

Avg. Gln uptake nmol*mg protein-1*30
sec-1

Cl- independent GlutamineUptake in RLE ATB0,+
0.25
0.2
0.15
0.1

*

0.05

*

0
EV

EV -Cl-

ATB0,+

ATB0,+ -Cl-

Figure 7: Na+-dependent/Cl- independent Glutamine (L-[3H] Gln) Initial-rate Uptake
in ATB0,+ Overexpressing RLE: The transport values obtained in the absence of
extracellular Na+ (diffusion and Na+ -independent uptake) were subtracted from those in
the presence of Na+ to yield Na+ dependent rates. Subsequently, Na+ dependent rates were
subtracted from those in the absence of Cl- to yield Cl- -independent rates. Data are the
average of at least four separate determinations ± SD. Asterisks (*) denote values that are
statistically significant with a P value < 0.050. EV= Empty Vector Na+/Cl- -dependent,
EV-Cl- = Empty Vector Cl- -independent, ATB0,+ = Na+/Cl- -dependent and ATB0,+ -Cl- =
Cl- -independent uptake

Avg. Arg uptake*nmol* mg
protein-130 sec-1

Arg uptake in RLE ATB0, + cells
0.25

*

0.2
0.15
0.1
0.05
0
RLE EV

RLE ATB0+

Figure 8: Na+/Cl- - dependent Arginine (L-(L-[3H] Arg) Initial-rate Uptake in
ATB0, + Overexpressing RLE. Asterisks (*) denote values that are statistically
significant with a P value < 0.050.
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Table 3: Ct (cycle threshold) values for RT- qPCR determining
abundance of the target gene (http://www.wvdl.wisc.edu/wpcontent/uploads/2013/01/WVDL.Info_.PCR_Ct_Values1.pdf)

Ct range

Amount of target
gene

Cts ≤ 29

Abundant

Cts of 30-37

Moderate

Cts of 38-40

Minimal

Table 4: RT-qPCR results for RLE overexpressing ASCT2

TRANSFECTANTCt
GENE
RLE EV - hASCT2

35.79

RLE EV - CANX

25.58

RLE EV - GAPDH

25.08

RLE ASCT2 - hASCT2

19.02

RLE ASCT2 - CANX

23.17

RLE ASCT2 - GAPDH

26.04

RLE overexpressing ASCT2 displayed a low Ct value of 19.02 as compared to the empty
vector control (RLE EV).
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Table 4: RT-qPCR results for RLE overexpressing ATB0,+
TRANSFECTANT-GENE
0,+

Reference
Genes

RLE EV - hATB

38.62

RLE EV - CANX

25.58

RLE EV - GAPDH

25.08

0,+

Reference
Genes

Ct

RLE ATB0+ - hATB

25.63

RLE ATB0+ - CANX

23.86

RLE ATB0+ - GAPDH

26.06

RLE overexpressing ATB0, + displayed a low Ct value of 25.63 as
compared to the empty vector control (RLE EV).

The Ct values indicated the over-expression of ASCT2 gene in RLE as Ct value for
target gene ASCT2 was 19.02 indicating a marked abundance of expression as compared to
the empty vector control (Ct = 35.79). The results also indicated an abundance of ATB0, + (Ct
value: 25.63) in comparison to the empty vector control (Ct = 38.62). Normally, the Ct
method would be used to calculate fold-increase in mRNA expression over control;
however, in these cases the fold-increase is infinite (calculated as 593,957-fold, and 32,316fold for ASCT2 and ATB0, +, respectively), as the measurement of a human transporter gene
in a rat cell line is performed. Essentially, calculating something from nothing. For the
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purposes of this study, the qPCR results simply confirm the abundant expression of both
transporters relative to the control.

Growth Studies
The expression of ASCT2 and ATB0, + transporters is upregulated in several cancers,
ostensibly due to increased demand for amino acids such as glutamine and arginine (Bode,
2017). Silencing of these transporters reduces cell viability and induces autophagy in cells
(Fuchs, et al., 2003; Geldermalsen, et al., 2015). Thus, it was conversely hypothesized that
their over-expression provides cancerous cells with a growth advantage through the
enhanced delivery of anabolic substrates and activation of various growth signaling
pathways including mTOR. To test whether ASCT2 or ATB0, + overexpression accelerates
the growth of cells, proliferation was assessed by the XTT assay. The results shown in
Figure 9 indicate that over-expression of ASCT2 and ATB0, + did not enhance growth rates
relative to the empty vector control. ATB0, + demonstrated higher growth rates initially but
unfortunately were unable to sustain the growth rates with time. This suggests that amino
acid delivery in cells is not necessarily rate-limiting for growth.
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XTT Assay
Growth in RLE transfectants

Abs (490 nm-630nm)

1.4
1.2
1
0.8
0.6
0.4
0.2
0
24-hr

48-hr

72-hr

96-hr

Time (hr)
RLE EV

RLE ASCT2

RLE ATB0+

Figure 9: Growth in RLE transfectants: Growth was measured using
the XTT assay. ASCT2 and ATB0,+ overexpressing RLE cells are shown
respective to the empty vector (EV) control cells.

While ASCT2 or ATB0, + overexpression did not lead to enhanced growth rates,
nonetheless, such observations of enhanced transporter expression in cancers may result in
other advantages to the cancerous cell. One possibility is an enhanced ability to take up
limited nutrients in an austere tumor microenvironment. To test this possibility, RLE cells
stably transfected with either transporter or empty vector (EV) were cultured in low
concentrations (1 μM or 10 μM) of glutamine. The results displayed in Figure 10 indicate
the opposite of that hypothesis. Both ASCT2 RLE or ATB0, + RLE cells progressively
decompensated with time and did not sustain growth in spite of the increased capacity to
take up glutamine. Potential reasons for this unexpected outcome are discussed later, but
likely the transporter overexpressing cells adapted to enhanced substrate delivery and down-
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regulated amino acid-linked growth signaling or metabolic pathways, and were unable to
adapt to acutely changing deficits in glutamine, and perished. Notably, the EV control cells
did not grow (compare to Figure 9), but instead appeared to growth arrest rather than die,
which supports this postulate.
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XTT Assay
Growth in 1 μM Gln
0.180

Abs(490nm-630nm)

0.160
0.140
0.120
0.100

RLE EV

0.080

RLE ASCT2

0.060

RLE ATB0+

0.040
0.020
0.000
24-hr

48-hr

72-hr

96-hr

Time (hr)

XTT Assay
Growth in 10 μM Gln

B

Abs(490nm-630nm)

0.350
0.300
0.250
0.200

RLE EV

0.150

RLE ASCT2

0.100

RLE ATB0+

0.050
0.000
24-hr

48-hr

72-hr

96-hr

Time (hr)

Figure 10: Growth in RLE transfectants in glutamine deprived conditions:
RLE cells stably transfected with ASCT2, ATB0, + , or empty vector (EV) were
plated at a concentration of 5,000 cells/well in a 96 well plate and were incubated at
37oC under 5% CO2/95% air overnight. The following day, media were changed to
DMEM (phenol red-free) + 10% dialyzed FBS supplemented with 1 μM glutamine
(A) or 10 μM glutamine (B), and allowed to incubate until growth was measured
using XTT assay. at 24, 48, 72 and 96 hours after media change.
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Physiological Contributions of Specific Transporters to Amino Acid Uptake
The original genesis of this research project was motivated by the desire to overexpress specific glutamine transporters in a basal cell line (RLE) and screen each for its
sensitivity to small molecular transport inhibitors. After months of work, RLE stably
overexpressing both ASCT2 and ATB0,+ were generated – two sodium-dependent
transporters implicated in cancer. After discovering that the overexpression of these
transporters conferred no apparent growth advantage in vitro, the question arose as to their
role in sustaining growth and the accumulation of key metabolic substrates, and the effects
of small molecular transport inhibitors on that function.
To assess the function of each transporter, RLE cells were allowed to transport
substrates (glutamine, arginine and leucine) over much longer periods (i.e., accumulation) of
time than the traditional initial-rate assays performed in transporter biology, which, by
design, focus on transporter contributions. These assays were also performed in normal
media (approximating physiological conditions) to better assess transporter contributions
under conditions in which the cells normally grow. Through the use of established small
molecular transport inhibitors, the relative contribution of endogenous (EV) and
overexpressed (ASCT2 and ATB0, +) transporters to delivery of substrates can be better
assessed and determined.
ASCT2 RLE and ATB0, + RLE accumulated glutamine much faster (and at
comparable rates) than EV controls cells (Figure 11). This result confirmed that both
glutamine transporters were over-expressed, and that differences in initial-rate transport
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between ASCT2 and ATB0, + (compare Figures 6 and 7) eventually dissipate and both
accumulate substrate at comparable rates, which are higher than controls (EV). Again, this
shows that enhanced glutamine delivery is not alone sufficient to drive accelerated growth.

Gln Uptake in RLE transfectants
Avg. Gln Upatke
nmol*mg protein-1

1.6
1.4
1.2
1
0.8
0.6
0.4
0.2
0
1 min

10 min

30 min

60 min

120 min

Time (min)
RLE EV

RLE ASCT2

RLE ATB0,+

Figure 11: Glutamine (L-[3H] Gln) transport under physiological conditions in
RLE transfectants: The transport of 1 mM glutamine (+ 3 μCi/ml L-[3H] Gln)
into RLE cells was measured in DMEM after 1, 10, 30, 60 and 120 min.

Elevated levels of Arginine derived NO have shown to be associated with protumorigenic and anti-apoptotic effects. ATB0, + mediates Na+/Cl- dependent influx of
arginine and has the ability to concentrate arginine inside the cells several-fold higher than
the extracellular medium (Gupta et al., 2005) . As expected, ATB0, + RLE cells accumulated
arginine significantly higher than ASCT2 RLE and EV control cells (Figure 12). These
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results again confirmed the specificity of both transporters, as ASTC2 displayed a very low
uptake of arginine, which is not one of its preferred substrates, unlike ATB0, +.
Arg Uptake in RLE transfectants
Avg. Arg Uptake rate
nmol*mg protein-1

1
0.8
0.6
0.4
0.2
0
1 min

10 min

30 min

60 min

120 min

Time (min)
RLE EV

RLE ASCT2

RLE ATB0+

Figure 12. Arginine (L-[3H] Arg) transport under physiological
conditions in RLE transfectants: The transport of 0.4 mM arginine (+
3 μCi/ml L-[3H] Arg) into RLE cells was measured after 1, 10, 30, 60
and 120 min.

A model has been proposed where ASCT2 works in conjunction with LAT1 in a
“tertiary active transport” arrangement, in which LAT1 brings in L-leucine in exchange for
L-glutamine (provided largely by ASCT2) to sustain mTOR growth signaling inside the cell
(Bode and Fuchs, 2005; Nicklin et al., 2009). Leucine is also a preferred substrate of
ATB0, +. Therefore, initial-rate and long term uptake and concentration of L-leucine by the
RLE stable transfectants was measured (Figure 13). Consistent with a role for ASCT2 in
driving leucine transport via LAT1, initial-rate (1 min) uptake rates were higher in ASCT2
transfectants, but diminish with time and subsequently converge with the EV control cells.
Conversely, ATB0, +. RLE cells exhibit the same initial-rate leucine uptake as controls, but
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accumulate leucine to higher levels after 2 hours, suggesting that it is a slow, concentrative
leucine transporter, consistent with its known qualities (Sloan and Mager, 1999).

Avg. Leu uptake
nmol*mg protein-1

Leu Uptake in RLE transfectants
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0
1 min

10 min

30 min

60 min

120 min

Time (min)
RLE EV

RLE ASCT2

RLE ATB0+

Figure 13: Leucine (L-[3H] Leu) transport under physiological conditions
in RLE transfectants: The transport of 0.1 mM leucine (+ 3 μCi/ml L-[3H]
Leu) into RLE cells was measured after 1, 10, 30, 60 and 120 min.
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Amino Acid Inhibition Studies
The study of amino acid transporters typically involves the measurement of initialrate transport activity in phosphate-buffered salts devoid of amino acids, which essentially
dissociates transport from metabolism. However, cells grow under long-term conditions,
both in vitro and in vivo in nutrient-rich environments, and individual transporters may play
distinct roles in maintaining amino acid economies inside the cell that are adaptive and
distinct from their measured initial-rate activities. In order to assess contributions of
individual transporters to initial rate uptake and long-term contributions to the metabolic
economies of the cell, the initial-rate and long-term transport of glutamine and arginine was
examined in the absence or presence of specific amino acid transporter inhibitors, outlined
in Table 6.

Table 6: Amino Acid Transport Inhibitors and their Preferred Transporters
Inhibitor

Preferred Transporter/s

BCH

SLC7 (LAT; LAT2; y+LAT1; y+LAT2)

GPNA

SLC1A5 (ASCT2)

MeAIB

SLC38 (SNAT1/2/4)

Betaine

SLC6A14 (ATB0, +)

Β-alanine

SLC6A14 (ATB0, +)
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GPNA or L-ϒ- glutamyl-p-nitroanilide inhibits glutamine uptake by ASCT2 at
micromolar levels. (Schulte et al., 2015).
MeAIB or alpha-(methylamino) isobutyric acid is a non-metabolizable amino acid
analogue used to distinguish System A and System N transporters (Bode, 2017). ASCT2
does not transport MeAIB (Pochini et al., 2014).
Betaine or tri methyl glycine is a subtype-selective amino acid for SNAT 2 (Nishimura, et
al., 2014).
β-alanine is a beta amino acid where the amino group is at the β position from the
carboxylate group. It is transported at low affinity by ATB0, +.
BCH or 2-aminobicyclo-(2,2,1)-heptane-2-carboxylic acid is a competitive inhibitor
of System L amino acid transporters leading to intracellular depletion of neutral amino
acids, primarily leucine, which is crucial for mTOR growth signaling (Kim et al., 2008).
ASCT2 does not readily transport BCH while ATB0, + is inhibited by BCH (Pochini et al.,
2014).
Figure 14 shows the effect of small molecular inhibitors on initial-rate uptake (1
min) of glutamine on transfectants. While effect of BCH was generally insignificant, there
was a 33% inhibition of glutamine uptake in RLE ATB0, + cells. Contrary to the expected
results, GPNA failed to inhibit the initial-rate glutamine uptake in RLE ASCT2 cells (̴ 14%
inhibition) under physiological conditions.
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Avg. Gln uptake nmol*mg protein-1min-1

Influence of AA inhibitors on initial-rate Glutamine uptake
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Figure 14: Influence of amino acid (AA) inhibitors on initial-rate glutamine
uptake: The transport of 10 µM glutamine (+ 3 μCi/ml L-[3H] Gln) into RLE cells was
measured after 1 min in DMEM in presence or absence of 5 mM BCH; 1 mM GPNA;
10 mM MeAIB; 10 mM Betaine or 10 mM β-alanine. Data are the average of at least
four separate determinations ± SD. Asterisks (*) denote values that are statistically
significant with a P value < 0.050.

On the other hand, uptake by RLE ATB0, + cells, was diminished by 66.7%, a result
which is consistent with the observation made in previous experiments in our lab where
GPNA was found to successfully inhibit glutamine uptake in transporters apart from
ASCT2. Although, it must be taken into consideration that the earlier experiments were
conducted in Na+ and Choline KRP (buffers traditionally used in transporter biology to
determine the substrates and sensitivity of transporters to inhibitors) and not under
physiological conditions. In presence of Betaine and β-alanine, RLE ASCT2 cells elicited an
enhancement in glutamine uptake.
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Avg. Gln uptake nmol*mg protein-1*60min-1
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Figure 15: Influence of amino acid (AA) inhibitors on long term glutamine
uptake: The transport of 10 µM glutamine (+ 3 μCi/ml L-[3H] Glu) into RLE
cells was measured after 60 min in DMEM in presence or absence of 5 mM
BCH; 1 mM GPNA; 10 mM MeAIB; 10 mM Betaine or 10 mM β-alanine. Data
are the average of atleast four separate determinations ± SD. Asterisks (*)
denote values that are statistically significant with a P value < 0.050.

Figure 15 shows the effect of inhibitors on long-term uptake or accumulation of
glutamine (60 min) on transfectants. The effect of inhibitors was markedly diminished on
long-term incubation. The accumulation of glutamine was found be steady across all the cell
lines. BCH had no effect on RLE ATB0, + cells this time. Similarly, GPNA failed to
significantly inhibit glutamine accumulation in any of the cell lines. Contrary to the
observation made in initial-rate uptake, betaine and β-alanine elicited an enhancement of
transport in RLE EV and RLE ATB0, + cells instead of RLE ASCT2.
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Figure 16: Influence of amino acid (AA) inhibitors on initial-rate arginine
uptake: The transport of 10 µM arginine (+ 3 μCi/ml L-[3H] Arg) into RLE
cells was measured after 1 min in DMEM in presence or absence of 5 mM
BCH; 1 mM GPNA; 10 mM MeAIB; 10 mM Betaine or 10 mM β-alanine.
Data are the average of at least four separate determinations ± SD. Asterisks
(*) denote values that are statistically significant with a P value < 0.050.

Figure 16 shows the effect of small molecular inhibitors on initial-rate Arginine
uptake (1 min) on transfectants. BCH had no effect on any of the cell lines. GPNA inhibited
arginine uptake by ̴ 50% in RLE EV cells, ̴ 33% in RLE ASCT2 cells and there was no
effect on RLE ATB0, + cells. These results suggest that GPNA may not be as effective under
physiological conditions as it is during conventional kinetic assays with KRP buffers. RLE
ATB0,+ cells exhibited accelerated arginine uptake rates in presence of MeAIB and betaine.
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Figure 17: Influence of amino acid (AA) inhibitors on long term arginine
uptake: The transport of 10 µM arginine (+ 3 μCi/ml L-[3H] Arg) into RLE
cells was measured after 60 min in DMEM in presence or absence of 5 mM
BCH; 1 mM GPNA; 10 mM MeAIB; 10 mM Betaine or 10 mM β-alanine.
Data are the average of at least four separate determinations ± SD. None of the
values were significant for this graph.
Figure 17 shows the effect of inhibitors on long-term arginine uptake or
accumulation (60 min) on transfectants. The uptake rates were found to be qualitatively
similar and in consistence with the previous results obtained for long-term glutamine
transport.

Avg.Leu uptake nmol*mg protein-1*min-1
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Figure 18: Influence of amino acid (AA) inhibitors on initial-rate leucine uptake: The
transport of 10 µM leucine (+ 3 μCi/ml L-[3H] Arg) into RLE cells was measured after 1 min
in DMEM in presence or absence of 5 mM BCH; 1 mM GPNA; 10 mM MeAIB; 10mM
Betaine or 10 mM β-alanine. Data are the average of at least four separate determinations
± SD. Asterisks (*) denote values that are statistically significant with a P value < 0.050.

Figure 18 shows the uptake of leucine in 1 min in absence and presence of inhibitors
by the transfectants. Though significant BCH was not able to substantially inhibit leucine
uptake by RLE ATB0, +. It only inhibited ̴ 36% transport in RLE EV, ̴ 33% in RLE ASCT2
and ̴ 30% in RLE ATB0, +. GPNA and other small molecular inhibitors were not able to have
any significant effect on leucine uptake.
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Figure 19: Influence of amino acid (AA) inhibitors on long term leucine uptake: The
transport of 10 µM leucine (+ 3 μCi/ml L-[3H] Arg) into RLE cells was measured after
60 min in DMEM in presence or absence of 5 mM BCH; 1 mM GPNA; 10 mM MeAIB;
10mM Betaine or 10 mM β-alanine. Data are the average of at least four separate
determinations ± SD. Asterisks (*) denote values that are statistically significant with a P
value < 0.050.

After 60 min, the effect of small molecular inhibitors on leucine uptake diminished
even further (figure 19). It reduced to only 32% in RLE EV, 24% in RLE ASCT2 and only
14% in RLE ATB0, +. The reduced inhibition can be attributed to the fact that the cells
started utilizing BCH as an enabler rather than an inhibitor after 60 min. There is a
possibility that it was transported out of the cell in exchange for more leucine. But further
investigation is required to confirm the validity of this theory.
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MeAIB showed no significant effect on transport activity suggesting no significant
role for system A in glutamine, arginine, or leucine import (figure 14-19). Likewise, Betaine
and β-alanine did not inhibit the transport activity by RLE ATB0, + cells. Instead, they
resulted in a slight increment in the uptake in certain cases (fig 14-16).

CHAPTER 4
DISCUSSION
Self-sufficiency in growth signals, capability to replicate indefinitely and evasion of
anti-growth mechanisms (insensitivity to anti-growth signals, evading apoptosis) are few of
the important hallmarks of cancer (Hanahan, Weinberg, 2010). Cellular proliferation plays a
central role in tumorigenesis and metabolic re-programming becomes a necessity to support
the continuous growth and to meet the increased demand for nutrients and building blocks in
the cell. Numerous studies have repeatedly shown the significant increase in consumption of
glutamine by rapidly proliferating cells in cancer. Glutamine is not only required by the cell
to synthesize a variety of macromolecules but glutamine-derived glutamate is required by
the TCA cycle for anaplerosis and oxidative ATP generation. Even in culture conditions,
the cell medium must be provided with supraphysiological concentrations of glutamine of 2
mM-4 mM in order to support optimal growth conditions (Bode, 2017). Thus, glutamine
metabolism becomes a potential therapeutic target for cancer therapies. The studies
presented here were undertaken to determine the physiological significance of
overexpressing two transporters implicated in driving cancer growth; ASCT2 (SLC1A5) and
ATB0, + (SLC6A14) on cellular growth and amino acid uptake and accumulation. Silencing
of these transporters inhibited cell proliferation and growth and activated apoptosis (Fuchs et
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al., 2007). However, in this study, over-expression of these transporters failed to exhibit
enhanced growth rates, indicating that endogenous transporter expression is not rate-limiting
for cellular growth.
ASCT2 is a high affinity glutamine transporter (Km ≈ 50μM) (Bode et al., 2002)
and is therefore upregulated in cancers to meet the increased demand for glutamine. In order
to address the possibility that enhanced ASCT2 expression may provide growth advantage
to the cells in nutrient deprived conditions, transfectants were assayed at depressed
glutamine concentrations (1µM & 10µM Gln). Normal physiological level of glutamine falls
between 600-1000μM (Bode, 2017). Growth assays showed dramatically reduced growth
rates in over-expressors compared to their empty vector control. These results suggest that
the transfected cells may have adapted to enhanced glutamine levels because of the
overexpressed transporters and consequently down-regulated their glutamine metabolizing
machinery. Spontaneous depletion of ambient glutamine concentrations disrupted the
glutamine economy in the cells resulting in chronically reduced growth rates.
Low growth rates under physiological conditions (1mM glutamine) can also be
attributed to low glutamine metabolism inside the cells for example, low endogenous
glutaminase activity, an amidohydrolase enzyme that generates glutamate and ammonia
from glutamine (Bode, 2017). In this scenario, sufficient levels of extracellular glutamine
and normal or alleviated expression of glutamine transporters on the plasma membrane may
fail to enhance the growth rates due to lack of metabolism. Further investigation is required
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to determine the effect of forced over-expression of glutamine transporters on glutaminase
expression and activity and thus overall glutamine metabolism inside the cell.
Forced over-expression of transporters exerts additional pressure on the cells. Thus,
more time and energy is required to produce the extra proteins. This can explain the
comparable growth rates of the over-expressors with the control under physiological
concentrations. In nutrient-limiting environment the over-expressors may not be able to
accelerate the production of the transporter proteins and consequently die due to lack of
glutamine-dependent bio-synthesis of essential metabolites and macromolecules.
In transporter biology, initial-rate uptake is traditionally used to distinguish amino
acid transporter activity from the subsequent amino acid metabolism. A cohort of transporter
proteins and enzymes work in concert to maintain amino acid homeostasis through substrate
accumulation, substrate retention followed by substrate metabolism. ASCT2 RLE and
ATB0,+ RLE exhibited enhanced uptake rates initially but the rates diminished with time and
became comparable to the empty vector control. These results are consistent with the
reduced growth rates observed earlier.
Small molecular transport inhibitors are used to assess the contribution of individual
transporters towards uptake of a substrate (short-term transport activity). The experiments in
this study were designed to test the utility of these inhibitors towards long-term transport
activity (metabolism of the substrate). Amino acid analogues like GPNA that are potent

50

inhibitors of initial-rate uptake, failed to significantly inhibit the long-term transport. The
un-repressed amino acid uptake can be attributed to several compensatory mechanisms.
There is a possibility that more than one potential amino acid transporter is expressed in
these cell lines. The attenuation of ASCT2 expression may have induced the expression of
transporters like y+LAT1 (SLC7A7) and y+LAT2 (SLC7A6) that also mediate the Na+
dependent uptake of neutral amino acids like glutamine (see figure 2). Likewise, lowaffinity systems like System A (transinhibited when intracellular amino acid pools are
satisfactory, even if expressed) may get relieved from transinhibition and eventually
contribute towards amino acid accumulation.
Ultimately, this study has shown that endogenous transporter overexpression does
not translate into increased growth rates in vitro nor is it rate-limiting for amino acid
metabolism under physiological conditions. These findings are consistent with the
diminished growth rates observed with RLE ASCT2 & RLE ATB0, + cells under glutamine
deprived conditions.
It should also be taken into consideration that RLE EV, RLE ASCT2 and RLE
ATB0, + cells were grown in a secluded environment with minimal intercellular competition.
The upregulation of these transporters may prove to be advantageous in a highly competitive
nutrient deprived tumor microenvironment where selective pressure comes into play. Further
in vivo analysis is required to determine the utility of the amino acid transporters in nutrient
deprived conditions and in establishing and sustaining amino acid metabolism.
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